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ABSTRACT
Background There is currently no Europe-wide
consensus on the appropriate preanalytical measures and
workﬂow to optimise procedures for tissue-based
molecular testing of non-small-cell lung cancer (NSCLC).
To address this, a group of lung cancer experts (see list
of authors) convened to discuss and propose standard
operating procedures (SOPs) for NSCLC.
Methods Based on earlier meetings and scientiﬁc
expertise on lung cancer, a multidisciplinary group
meeting was aligned. The aim was to include all relevant
aspects concerning NSCLC diagnosis. After careful
consideration, the following topics were selected and
each was reviewed by the experts: surgical resection and
sampling; biopsy procedures for analysis; preanalytical
and other variables affecting quality of tissue; tissue
conservation; testing procedures for epidermal growth
factor receptor, anaplastic lymphoma kinase and ROS
proto-oncogene 1, receptor tyrosine kinase (ROS1) in
lung tissue and cytological specimens; as well as
standardised reporting and quality control (QC). Finally,
an optimal workﬂow was described.
Results Suggested optimal procedures and workﬂows
are discussed in detail. The broad consensus was that
the complex workﬂow presented can only be executed
effectively by an interdisciplinary approach using a well-
trained team.
Conclusions To optimise diagnosis and treatment of
patients with NSCLC, it is essential to establish SOPs
that are adaptable to the local situation. In addition, a
continuous QC system and a local multidisciplinary
tumour-type-oriented board are essential.
INTRODUCTION
The majority of patients with suspected lung cancer
require tissue biopsy to conﬁrm the diagnosis.
Many patients will present with advanced disease,
where mutation testing for targeted treatment is
now considered to be the standard of care.
In non-small-cell lung cancer (NSCLC), analysis of
epidermal growth factor receptor (EGFR) mutations
and anaplastic lymphoma kinase (ALK) inversions/
translocations are prerequisites for determining the
appropriate tyrosine kinase inhibitor to be used in
targeted treatment in order to improve patient out-
comes and survival.1 2 Besides several other targets
that are tested within clinical trials, the ROS proto-
oncogene 1, receptor tyrosine kinase (ROS1) seems
to be the third genetic alteration that needs to be
implemented in the routine testing procedure.3–5
There is no current Europe-wide consensus con-
cerning these aspects. Moreover, a structured rec-
ommendation (best practice) and overview for
tissue diagnosis and molecular testing in NSCLC is
missing. To obtain best results, standard operating
procedures (SOPs) are required to optimise clinical
sampling, tissue processing, testing, reporting,
timing and quality control (QC). In addition, to
ensure an adequate workﬂow, a local interdisciplin-
ary tumour board is absolutely essential. Adherence
to best practice in molecular testing of NSCLC is
vital to ensure accurate diagnoses and appropriate
clinical decisions. Therefore, a European multidis-
ciplinary lung cancer group convened and discussed
these above-mentioned aspects. This article sum-
marises their particular statements.
MATERIALS AND METHODS
To agree recommendations on tissue sampling for
diagnosis and molecular testing procedures for
NSCLC, a group of European interdisciplinary
NSCLC experts convened in Berlin in November
2013. One aim of this activity was to gather infor-
mation from all physicians involved in the diagnosis
and treatment of patients on the importance of the
different steps towards optimal diagnosis and treat-
ment. The current paper presents an overview of
the essential steps recommended by this group. The
experts were selected by MD, ET, KMK and FL-R.
The selection procedure was based on a number of
earlier meetings involving these individuals when a
range of issues relating to NSCLC diagnostics were
discussed. These scientiﬁcally acknowledged
experts in the ﬁeld were individually invited to the
meeting, to present their data and to share their
experiences, with a view to producing a consensus
publication. At the outset of the meeting in Berlin,
the structure of the process and the main topics
were discussed and agreed by the group. Each indi-
vidual participant made a presentation to the
group, a broad discussion took place, the main
issues were identiﬁed and a consensus position was
reached. Finally, the experts agreed to write the
corresponding section of a consensus manuscript
on their particular topic and MD and MvL were
asked to merge the different contributions together
into a structured, consensus paper. The draft was
then circulated several times among the participants
for ﬁnal editing and completion. The meeting was
funded by Pﬁzer (Europe), but the latter had no
input into the paper content.
Open Access
Scan to access more
free content
Dietel M, et al. Thorax 2016;71:177–184. doi:10.1136/thoraxjnl-2014-206677 177
Review
RESULTS
Diagnosis, tissue sampling and staging: role of the thoracic
surgeon
Most patients with suspected lung cancer require a tissue-based
diagnosis. The aims of tissue sampling include conﬁrmation of
diagnosis (eg, adenocarcinoma vs squamous cell carcinoma) and
molecular testing.6 Individual patient care by a multidisciplinary
team is best practice to decide individualised diagnostic and
therapeutic plans.7 Preliminary staging investigations such as CT
and positron emission tomography/CT are often helpful to
guide invasive sampling. Where possible, the least invasive
method of biopsy is undertaken.
Distant metastases, if accessible, may be the ﬁrst site of punc-
ture or biopsy, as these tissues can provide diagnostic and
staging information (proof of M1b disease). Cervical mediasti-
noscopy, thoracoscopy and related procedures allow biopsies of
every mediastinal lymph node station (stations 1–9) or pulmon-
ary parenchymal lesion. These procedures provide large
samples, but require general anaesthesia. With the latter two
techniques, false-negative rates are below 10%, increasing the
sensitivity of the method used.8 9 In more difﬁcult cases, thora-
coscopy can also be used to perform wedge excisions of suspi-
cious lung nodules or take biopsies of suspect pleural lesions
which are difﬁcult to reach by another method.
At each assessment centre, a precise workﬂow for transporta-
tion of samples should be optimised, with an established SOP to
reduce transportation time to the diagnostic and molecular
pathologists.
Summary
▸ In patients in whom lung cancer is suspected, a tissue diagno-
sis should be obtained.
▸ Each patient’s case should be discussed within a multidiscip-
linary team to provide an individualised diagnostic and thera-
peutic plan.
▸ The least invasive method of biopsy is preferred, although in
some cases invasive procedures may be necessary.
▸ A SOP should be established for transportation of tissue
samples and biopsies.
Biopsy procedures and sampling for analysis
Approximately 80% of patients with NSCLC present or relapse
with advanced disease. As described above, these patients need
highly qualiﬁed diagnostic procedures.
Flexible videobronchoscopy
Taking histological biopsies is preferred over brushes and cyto-
logical washes. When an endobronchial tumour is visible during
ﬂexible videobronchoscopy, a diagnostic yield of at least 85%
should be obtained.10 A diagnostic yield of 70% or more should
be obtained when modern guidance techniques are used to diag-
nose a peripheral tumour >20 mm in size, invisible during
bronchoscopy but in proximity to a patent bronchus. In order
to optimise diagnostic yield and allow histopathological tumour
subtyping and genotyping, at least ﬁve endobronchial/transbron-
chial forceps biopsies should be obtained.11 12 An additional
ﬁve bronchial forceps biopsies should be considered in order to
maximise the volume of tissue for NSCLC phenotyping and
genotyping. Alternatively, two cryobiopsies may be taken during
ﬂexible bronchoscopy. Endobronchial ultrasound (EBUS) with
transbronchial needle aspiration using a 21–22 G needle has a
diagnostic yield of at least 90% in enlarged or bulky lymph
nodes. Oesophageal ultrasonography is able to reach stations 8
and 9, and can also access the left adrenal gland, left liver lobe
and coeliac trunk lymph nodes. At least four needle aspiration
passes per target lesion are recommended to provide sufﬁcient
tissue for genotyping.13
Ideally, the pulmonary physician or radiologist performing
the biopsy procedure is aliquoting the different biopsies to the
laboratory in individual containers.
Radiology-guided percutaneous biopsy
CT-guided coaxial core biopsy is preferred over aspiration
cytology when possible, as it allows multiple and larger samples
to be obtained with a single puncture. Careful case selection
and technical considerations are necessary to increase diagnostic
yield and avoid unnecessary complications.14
A diagnostic yield of at least 90% should be obtained when
the target lesion to biopsy is in proximity to the chest wall and
>15 mm in size.15 At least two core needle biopsies are recom-
mended, using an 18–20 G needle. To maximise the volume of
tissue for histological subtyping and genotyping, 3–6 core
needle biopsies could be considered as long as the safety of the
procedure can be guaranteed. Depending on local expertise and
availability of techniques, either a CT or an ultrasound-guided
percutaneous core needle biopsy can be performed from the
primary tumour or a metastatic site (pleural, liver, bone, adrenal
gland, peripheral nodal metastasis, etc). The most frequent com-
plications are pneumothorax and haemorrhage, although these
are usually of little concern. Only 1–4% of pneumothorax cases
require tube placement. Air embolism and tumour seeding are
extremely rare.
Summary
▸ At least ﬁve endobronchial/transbronchial forceps biopsies
should be taken; to maximise the volume of tissue, an add-
itional ﬁve forceps biopsies or two cryobiopsies could be
considered.
▸ At least four EBUS/endoscopic ultrasound needle aspiration
passes per target lesion are recommended.
▸ At least two percutaneous core needle biopsies using an 18–
20 G needle should be taken; in order to maximise the
volume of tissue, 3–6 core needle biopsies could be
considered.
Handling of tissue (macroscopy)
Biopsies are transferred immediately to the labs (institutes of
pathology), are formalin-ﬁxed and embedded in parafﬁn. Prior
to ﬁxation and embedding, operative material (eg, lobectomy) is
initially handled macroscopically (documentation and gross sec-
tioning) after a standardised protocol.16 The hilus and the tissue
margin (the latter depending on the operation procedure) need
to be taken to tell about the R(esection)-status. The operative
material is cut into sections (thickness 5–10 mm) and the
tumour is measured as this will classify the pT-stadium.17
Measuring also includes the distance of the tumour to the resec-
tions margins; furthermore, pleura inﬁltration needs to be docu-
mented. A total of 3–5 tumour sections are taken, as well as an
additional representative section of non-tumour tissue. Small
tumours should be embedded completely.
Preanalytical variables and factors affecting quality of
biopsies and surgical samples
Before the pathologist can process surgical samples and biopsies,
preanalytical variables affecting sample quality need to be
considered.
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Minimal amount of tissue/cells required for reliable analyses
Several immunohistochemical markers may need to be analysed
to conﬁrm and subtype NSCLC.18 Additional material is
required if a range of tests are planned in the context of perso-
nalised medicine, using immunohistochemistry (IHC), in situ
hybridisation (ISH) or sequencing techniques. For these proce-
dures, sufﬁcient material of good quality is required.19 In the
majority of cases, especially for patients with advanced lung
cancer, diagnostic material might be sparse, containing only a
small amount of tumour cells, on which all diagnostic tests must
be performed. Small biopsy samples with a small number of
tumour cells might only allow diagnosis and classiﬁcation of
tumour type (eg, adenocarcinoma), but additional molecular
tests may be compromised.
Preanalytical considerations
To standardise the work-up of resection material, vacuum pres-
ervation might be considered.20 Immediately after removal, the
material can be preserved by sealing under vacuum in special
plastic bags and placing it in a controlled environment (4°C). It
is important that these procedures are conducted in a standar-
dised way.
Warm and cold ischaemia time should be as short as possible.
It may be valuable to record ischaemia time, as this may impact
on subsequent analyses. This ‘time delay’ between tissue acquisi-
tion and ﬁxation depends on environmental temperature and
should be shorter than 30 min. In general, a consecutive ﬁxation
period in buffered formalin of 6–48 h before parafﬁn embedding
is recommended (depending on the volume of material). This
will permit adequate DNA quality and most IHC-detectable anti-
gens will survive. Although RNA is more labile and deteriorates
rapidly, the latest quantitative real-time PCR tests can analyse
RNA in formalin-ﬁxed, parafﬁn-embedded (FFPE) samples (eg,
the EndoPredict breast cancer assay).21 Other ﬁxatives, such as
Hepes-glutamic acid buffer-mediated Organic solvent Protection
Effect (HOPE), FineFix and alcohol, did not prove to be superior
to buffered formalin and did not ﬁnd widespread acceptance.
Organisation and optimisation of sectioning
To maximise tissue availability, two strategies may be employed.
The ﬁrst is to perform minimally invasive sectioning for an
initial look and a preliminary diagnosis—a ‘touch and go’
approach. This differs signiﬁcantly from the standard technique
practised by most technicians, who are trained to cut deep
into the block to make sure the largest diameter of the biopsy is
on the initial slides. The other strategy is to cut multiple
(approximately 20) unstained sections and keep them stored
until a preliminary diagnosis has been made and ancillary
testing is requested. Cutting should only be done by the most
experienced technicians, using microtomes equipped with
‘waterfall’ slides to make use of every section. Ultra-thin sections
(approximately 2 mm) are excellent for routine staining and
IHC. Finally, the frequency of re-cutting blocks should be mini-
mised—ideally, sections for all ancillary tests should be cut in
the same session.
To achieve high-quality molecular testing, it is important that
the pathologist marks the most suitable tumour area in the slide
so that the optimal tumour content is extracted from the
parafﬁn-embedded material.5 The most adequate procedure
appears to be manual microdissection (ﬁgure 1). If several tissue
blocks are available, the tumour area with the least amount of
necrosis, blood, mucous or inﬂammation should be selected.
The quantitative relationship of tumour cells to non-tumour
cells is also of critical importance; if possible, a minimum of
20–30% of tumour cells should be present in material tested for
genetic alterations to minimise false-negative results.
Practical suggestions
Standardised algorithms for the diagnostic procedures should be
deﬁned in current routine practice.22 This should involve reﬂex
sectioning for IHC and/or molecular testing, which will shorten
turnaround time and preserve tissue (see ﬁgure 2).23 The ﬁrst
set of slides is required for H&E, PAS and IHC characterisation
for TTF1 and p40 or p63, complemented by CK5/6, napsin or
CK7 if necessary. First of all, this will ensure the diagnosis and
Figure 1 Importance of manual
microdissection as a prerequisite for
reliable and reproducible analyses in
molecular pathology. (A–D) A typical
lung specimen with ﬁve biopsies, of
which one contained malignant cells;
only this biopsy should be used for
molecular analyses. The tumour area
must therefore be primarily prepared
microscopically from the parafﬁn block
before being analysed. (E) Further
analytical steps. (F) Example of a
pathology report combining
morphological and molecular results as
a prerequisite for treatment of a
patient with a targeted drug. (G) All
tests should be accompanied by
external quality assurance, such as
‘Qualitätssicherungs-Initiative
Pathologie’ (QuIP).
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helps to differentiate between adenocarcinoma and squamous
cell carcinoma (or not otherwise speciﬁed). Parallel predictive
IHC (eg, ALK, c-MET, ROS) might be performed. Genetic ana-
lyses for EGFR and ﬂuorescent in situ hybridisation (FISH) for
ALK are considered routine steps. The analyses of RAS, BRAF,
MET, ROS and RET can be considered, if clinically appropriate.
Especially ROS1 is more and more requested for testing due to
promising study results. So far, FISH seems to be the gold stand-
ard, IHC is possible but not well standardised.24 Since most of
these mutations are mutually exclusive, a pragmatic approach
would be to perform sequential testing. However, this is
time-consuming, and co-mutations were observed indicating
intrinsic or acquired therapy resistance.
Summary
▸ Optimise transfer of tissues from operating theatre to path-
ology laboratory.
▸ Perform appropriate ﬁxation as early as possible (between 6
and 48 h).
▸ Aliquoting of biopsy tissue to individual containers and
blocks.
▸ Cut extra sections at the ﬁrst cutting session to avoid tissue
waste, especially if the amount of tissue is low.
▸ Deﬁne parallel IHC-staining to shorten turnaround times
(5–10 days), saving tissue and reducing costs.
▸ Use of controlled, tissue-conserving tumour cell enrichment
techniques supervised by an experienced pathologist to select
the most appropriate tumour area (manual microdissection)
for DNA extraction and molecular testing.
Testing procedures for detection of EGFR and ALK status in
lung tissue
Mutations in the EGFR gene occur in the intracellular domain,
in particular the tyrosine kinase domain, in approximately 7%
of resected NSCLC cases and 13% of adenocarcinomas.25
Deletions in exon 19 and the L858R point mutation in exon 21
are the most frequent mutations. The appropriate methods to
detect EGFR mutations are Sanger, pyrosequencing and next-
generation sequencing (NGS) (platform dependent).
Several methods for detecting ALK gene rearrangements are
available, including FISH, IHC, reverse transcriptase (RT)-PCR
and NGS.19 In the USA, ALK FISH is the method of choice,
while in Europe, approval for ALK-positive lung cancer also
allows other ALK validated tests.19
Currently, three antibodies, ALK1, 5A4 and D5F3, have been
tested for ALK IHC-positive lung cancer, with 5A4 and D5F3
Figure 2 A realistic approach for sample prioritisation for the study of predictive biomarkers in patients with advanced lung adenocarcinomas.
Route A is for cases that require classiﬁcatory immunohistochemistry (IHC), while route B is for cases that are diagnosed based on H&E staining
alone. The relative frequency of the different genetic alterations is shown in parentheses. Adapted from Conde et al,23 under the Creative Commons
Attribution licence (CC BY). AC, adenocarcinoma; ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homologue B1;
EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homologue; NSCLC-NOS, non-small-cell lung cancer-not otherwise speciﬁed; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase.
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providing the best results.19 There is a high correlation between
FISH and IHC, although some discrepant cases have been
reported.19 26
There are two different RT-PCR approaches for ALK testing.
One uses probes for both fusion genes (ALK and EML4/KIF5B/
HIP133),27–30 while the other compares different levels of amp-
liﬁcation of small PCR products (50 and 30 portions of ALK
transcripts) on the ALK gene (fusion partner independent).31 32
The ﬁrst approach has a sensitivity of approximately 90%
(depending on the coverage of fusion partners), while theoretic-
ally the latter approach has 100% sensitivity. Different mechan-
isms for resistance exist in lung cancer with ALK gene
rearrangement, demonstrating the need for tissue sampling
before making new treatment decisions.33 34
Summary
▸ EGFR and ALK status should be determined in locally
advanced/metastasised lung adenocarcinomas for prediction
and treatment.
▸ In recurrent tumours, and tumours treated with
EGFR-targeted or ALK-targeted therapies, newly growing
lesions should be re-biopsied and tested to determine
mechanisms of resistance, possibly uncovering other treat-
ment options.
ALK analysis in cytological specimens
As many as 40% of all lung cancers are diagnosed by cytology
without concurrent biopsy material, necessitating predictive
marker testing of cytological specimens. Initial concerns and
prejudices regarding cytological predictive marker testing in
lung cancer have disappeared and it is now widely recognised
that cytological specimens are suitable for PCR-based or
FISH-based predictive marker analyses. Cytological diagnosis is
explicitly referred to in recommendations.2 18 19
Cytology procedures and preanalytics
Cytological diagnosis of lung cancer is typically based on
EBUS-ﬁne needle aspiration (FNA), bronchial cytology, pleural
effusions and FNA from distant metastases. The presence of a
cytopathologist or a trained cytotechnician during the procedure
of EBUS-FNA has become a standard in some institutions in
order to ensure an appropriate amount of tumour cells in the
sample. FFPE cell blocks are the preferred method for processing
cytological specimens in many laboratories, as they can be
handled like histological specimens and provide long-term pres-
ervation of proteins. However, cell blocks are not always avail-
able and a signiﬁcant subset of cell blocks contain insufﬁcient
cancer cells for molecular analysis.35 In addition, differentiating
tumour cells from adjacent reactive cells in cell blocks is more
challenging than in conventional cytology, especially during
FISH analysis. In air-dried or alcohol-ﬁxed cytological speci-
mens, DNA quality is better than that of formaldehyde ﬁxation,
which leads to crosslinking and chemical modiﬁcation of nucleo-
tides. This explains the high success rate (close to 100%) for ALK
FISH analysis in conventional cytology and a failure rate of up to
19% for histological specimens reported by Savic et al.36
ALK FISH analysis in cytology
FISH is a robust technology applicable to almost all types and
formats of cytological specimens, including conventional
smears, cytospins or liquid-based preparations. The use of
adhesive-coated and positively charged slides is recommended
to improve the adherence of the cells and prevent them from
ﬂoating off during technical FISH procedures. FISH works
equally well on unstained specimens as well as those stained
with Papanicolaou, H&E or May-Grünwald-Giemsa; a respect-
ive protocol has been published.2
Precise relocation of tumour cells using an automated stage
greatly facilitates FISH scoring and review, especially in cases
with a low proportion of tumour cells on the slide.26
ALK IHC in cytology
ALK IHC is a promising method for preselecting cytological spe-
cimens for FISH testing, and may even remove the need for FISH
analysis. In a recent study of ALK IHC using the 5A4 antibody,
the accuracy of ALK detection on Papanicolaou-stained cyto-
logical slides was high, with a sensitivity and speciﬁcity of almost
100% compared with ALK FISH.37 ALK IHC of cytological spe-
cimens also works with other appropriate antibodies (eg, D5F3)
and immunostainers, provided the appropriate protocols are
being developed. For cell blocks, existing protocols and assays
for ALK IHC of histological specimens can be applied.
Summary
▸ Histological and cytological specimens should be reviewed
jointly to select the most appropriate specimens for bio-
marker analysis.
▸ ALK analysis (IHC and FISH) is applicable to both cytospins/
smears and cell blocks.
▸ ALK analysis of cytospins and liquid-based specimens
requires different technical protocols to those used with cell
blocks and histology.
Reporting test results
The aim of a molecular pathology report is to clearly communi-
cate the results to clinicians in a language that is understandable
to an oncologist or a fellow general pathologist. Any limitations
and uncertainties in the test results should be explicitly commu-
nicated. Several published recommendations exist on how to
format molecular test reports in general and NSCLC testing in
particular; here, we will focus on integrated molecular reports
written by the pathologist and important details that should be
included in the respective sections of a test report.
Integrated (combined) molecular reports written by the
pathologist
If molecular predictive testing is performed as an in-house reﬂex
test, the results should preferably be reported as an addendum
to the original report rather than being written as a stand-alone
report. Ideally, the results and interpretations should be inte-
grated as much as possible and written up by the pathologist.
Preanalytical section
Important parameters such as cold ischaemia time, ﬁxative and
ﬁxation time need to be reported. If tumour cell enrichment is
performed, the method of dissection must be denoted (eg, laser
capture microdissection, manual microscopic, manual without
microscopic, tissue core or whole section). The ﬁnal content of
tumour cells, expressed as percentage of total cells/nuclei, and
the amount of DNA should be stated. Findings such as extensive
necrosis, inﬂammation, pigmentation or borderline tumour cell
content may be highlighted. An important control step is to
inspect the last section after the material required for molecular
analysis has been cut.
Results section
For clinically signiﬁcant mutations, formal designations accord-
ing to Human Genome Variation Society nomenclature should
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be presented together with a more colloquial locally acceptable
nomenclature. Single nucleotide polymorphisms and variants of
uncertain clinical signiﬁcance need to be communicated.
Although the International System for Cytogenetic
Nomenclature can be used to describe chromosomal structural
changes (eg, translocations and ampliﬁcations), many oncolo-
gists and pathologists are unfamiliar with this system and will
also require terminology in common usage. For ISH-based tests,
the number of cells analysed and the number and percentage of
positive events should be stated. For multiplexed analyses or
NGS results, a tabulated format is recommended. Inconclusive
test results should be reported as such and the reason for the
failure, if known, should be explained.
Interpretation section (commentary)
A statement of the probability of the cancer responding to or resist-
ing speciﬁc targeted therapy should be included in this section.
Technical section
Sufﬁcient technical information should be provided to enable
another molecular pathologist to understand how testing was
performed. Known limitations of tests need to be stated, and if
positive and negative predictive values are published they need to
be declared. The validation (IVD; CE; FDA) and accreditation
(ISO; CAP) status of each test relays important information.
Summary
▸ Molecular test data reported by the pathologist and inte-
grated as an addendum to original reports represent the
optimal solution.
▸ Documentation of critical preanalytical factors, such as cold
ischaemia and ﬁxation time, represents an important ﬁrst
step in achieving better control of these factors.
▸ Communication of results according to established inter-
national consensus systems is necessary.
Timing of testing and reporting
There is increasing focus on reducing the interval between
patients being referred to specialist care and the time treatment
is started, as this may inﬂuence prognosis.38 Generally, clinicians
expect to see a ﬁnal molecular test report within ﬁve working
days after the laboratory receives the specimen. After a con-
ﬁrmed diagnosis of NSCLC, transfer times between departments
and the start of molecular testing must be kept to a minimum
(<24 h). If tissue samples need to be sent to an outside labora-
tory for molecular testing, routines should be established so that
unstained sections can be mailed within three working days
after receiving the request or establishing ﬁnal diagnosis if a
reﬂex testing protocol exists. Here, we discuss relevant aspects
of the timing of molecular tests and test reports.
Preselection of suitable testing material in routine pathology
laboratory
Whenever a diagnosis of NSCLC is made from cytological,
biopsy or surgical specimens, a section in the report should
mention which slide or block is most suitable for ancillary
molecular testing. A marked indication of the optimal tumour
area on the selected slide and an estimate of tumour cell content
should be given in the report.
Predeﬁned panels and testing algorithms
A multidisciplinary group should make recommendations on a
predictive test panel for NSCLC. A consensus decision for reﬂex
upfront testing on initial diagnosis of NSCLC is optimal.
Parallel testing using multiplexing or NGS techniques is
recommended.39
Early trigger point
Predictive molecular testing should be initiated when the ﬁrst
H&E sections conﬁrm probable NSCLC.
Digital pathology
Digital pathology holds great promise for reducing handling
times and selecting the most appropriate tissue for analysis. The
molecular pathologist can also decide if tumour cell enrichment
techniques such as microdissection need to be used; if so, areas
of interest can be indicated in the digitised image.
SOPs, including secretarial issues
In order to keep handling times for request forms, specimen
requisitions and reporting to a minimum, it is very important to
establish a SOP that includes the secretarial staff. Simple mea-
sures such as opening request forms addressed to individual
doctors and scheduling a molecular pathologist for prioritised
handling are essential.
Electronic standard reports and LIS–HIS networks
The utilisation of modern laboratory information systems (LIS)
with built-in synoptic report generators for predictive molecular
testing in NSCLC will signiﬁcantly cut turnaround times. A
good hospital information system (HIS) connected to all
regional care providers and properly linked to the LIS should
guarantee that results are transferred to the patient’s physician
immediately after the report is signed.
Summary
▸ Predeﬁned test panels and algorithms including reﬂex and
parallel testing, agreed by the multidisciplinary team, are
recommended.
▸ Clear indication of the most suitable slide or block for pre-
dictive molecular testing and characterisation of tumour cell
content should be included in the routine surgical pathology
report.
▸ Utilisation of digital pathology to select suitable test material
from digital archive and selection of area for tumour cell
enrichment shorten handling time and costs.
▸ A SOP including secretarial handling of request forms and
specimen requisitions needs to be established.
External quality assessment/QC
External quality assessment/QC at the European level
External quality assessment (EQA) is a systematic process for
assessment of diagnostic and predictive tests, where a number of
test samples are distributed to participating centres and subse-
quent test results are analysed. The goal is to achieve a high
level of accuracy and reproducibility among different labs.
Reaching this goal is vital to enable valid comparisons of global
treatments, especially in the era of personalised therapy.
EQA programmes from various organisations have been in
place since the beginning of molecular diagnostics. For predictive
testing in NSCLC, reports have been published for EGFR40–42
and KRAS42 mutational analysis, and ALK.43 44 Guidelines for
standardisation of EQA schemes have recently been
introduced.45
EQA/QC at the national level
The QuIP initiative (‘Qualitätssicherungs-Initiative Pathologie’)
in Germany, Switzerland and Austria is an example of QC at the
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national level. To identify institutions capable of providing high-
quality molecular testing, QuIP organises EQAs procedures for
different diagnostic applications. Until now, two ALK-QCs
(based on ISH) had been enrolled in Germany, Switzerland and
Austria: The ﬁrst was performed at the end of 2012; 60.3%
(32/53) of the participating institutes passed the EQA and were
certiﬁed for ALK testing.43 The second ALK-QC took place at
the beginning of 2014; in this programme, a total of 92.5%
(37/40) of participating institutes passed the EQA, demonstrat-
ing a successful learning curve. EQAs might also help to gain
experience in potential additional testing methods: ALK IHC
was highlighted as an effective method for multicentre applica-
tion, if carefully validated.39 43 44
In June 2014, a joint agreement was signed by the German
Society of Pathology, the Association of German Pathologists
and the European Society of Pathology. Each organisation
accepts the other’s quality assessment process, and ofﬁcial docu-
ments (eg, certiﬁcation) will be signed accordingly.
Recommendations for QC at the national/European level
▸ Sufﬁcient performance in EQA schemes is crucial for com-
parison of global predictive biomarker studies.
▸ QC programmes (EQA) at the national and/or European
level aim to provide a high level of accuracy and standardisa-
tion in predictive molecular testing.
▸ Pathology institutes should participate regularly in order to
remain certiﬁed within EQA programmes.
▸ Only certiﬁed institutions should perform prognostic and
predictive tests.
Tumour heterogeneity
Tumour heterogeneity is an issue one must be aware of, espe-
cially in the context of molecular diagnostics. Concerning renal
clear cell carcinoma (RCC), this has been investigated in detail
by Swanton and coworkers, showing that single RCCs harbour
areas with different frequencies of mutations, suggesting the
concept of main mutations (early development) and subclonal
mutations (later development). This may provoke that biopsies
do not represent a representative image of the tumour (the same
can be true for metastasis).46 47
Concerning lung cancer, these aspects had been discussed for
EGFR: time to disease progression and overall survival after
geﬁtinib treatment were signiﬁcantly shorter in those patients
with EGFR heterogeneity.48
Concerning ALK, Camidge and coworkers showed different
amounts of FISH-positive tumour cells within one tumour.
However, they discussed this to be due to methodological rather
than biological reasons.49
Furthermore, it was shown that so-called borderline cases
with FISH positivity around the cut-off of 15% showed expres-
sion of the ALK-protein by IHC in nearly all tumour samples.22
To summarise, the role of intratumoural (spatial) heterogeneity
is a growing concept that needs to be considered, especially
when comparing biopsy and resections specimen, as well as
primary site and metastasis. Upcoming NGS-based studies might
help to further clarify these aspects and give answer to the ques-
tion to what extent arbitrary results are due to biological and/or
methodological reasons.
CONCLUSIONS
Pathobiological understanding, diagnostic accuracy and treat-
ment options for NSCLC are rapidly evolving, leading to
improvements in outcomes for many patients. This rapid evolu-
tion is driven by the new era of molecular targeted therapies
with kinase inhibitors, and also by recent developments in the
workﬂow of patient care, in particular:
▸ Better clinical diagnostics
▸ Reﬁned sampling techniques
▸ Improved preanalytic measures of tissue handling
▸ Much more precise histological diagnoses, combined with
– New tissue-based or cytology-based molecular pathology
assays
– Standardised reporting and
– Continuous external QC.
To bring together all these factors and optimise their effective-
ness, multidisciplinary panels comprised of personnel experienced
in different areas of cancer care are essential and may be key to
further beneﬁts. Thus, patients should be treated only in compre-
hensive cancer centres where these prerequisites are in place.
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